

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau28 GEN. 1999
D
u
↓
De

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/405, 31/205	A1	(11) International Publication Number: WO 99/01126 (43) International Publication Date: 14 January 1999 (14.01.99)
<p>(21) International Application Number: PCT/IT98/00163</p> <p>(22) International Filing Date: 18 June 1998 (18.06.98)</p> <p>(30) Priority Data: RM97A000390 1 July 1997 (01.07.97) IT</p> <p>(71) Applicant (for all designated States except US): SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. [IT/IT]; Viale Shakespeare, 47, I-00144 Roma (IT).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): CAVAZZA, Claudio [IT/IT]; Piazza Campitelli, 2, I-00186 Roma (IT).</p> <p>(74) Common Representative: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.; Viale Shakespeare, 47, I-00144 Roma (IT).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING ALKANOYL L-CARNITINE IN COMBINATION WITH A STATINE FOR TREATING PATHOLOGIES BROUGHT ABOUT BY AN ALTERED LIPID METABOLISM</p> <p>(57) Abstract</p> <p>The co-ordinated use of an alkanoyl L-carnitine (e.g. propionyl L-carnitine) and a statine (e.g. simvastatin) is disclosed for treating pathologies brought about by an altered lipid metabolism, wherein by co-ordinated use both the substantially contemporaneous co-administration of the two active ingredients and the administration of a combination composition comprising a mixture of the two active ingredients, is meant.</p>		